This is attributed to the fact that per definition the mutations first looked for and identified in CHIP carriers are frequently found in myeloid malignancies, and to the subsequent confirming observation that most CHIP carriers have an increased risk of developing myeloid but not lymphoid neoplasms [15]. This evidence concerns the gene STUB1 and lymphoid neoplasm.